LB Pharmaceuticals Inc LBRX
38.85 USD -1.19 (-2.97%)
Regular-session close
38.85 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
38.57 Day range 40.67
15.33 52-week range 49.48
- YTD
- +74.53%
- 1 year
- +146.04%
News
seekingalpha.com Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those…
globenewswire.com LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G. Kozauer, M.D.
marketbeat.com LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia LB Pharmaceuticals NASDAQ: LBRX outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day…
globenewswire.com LB Pharmaceuticals to Participate in Upcoming Investor Events NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
globenewswire.com LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
defenseworld.net LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62 LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One…
seekingalpha.com LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables…
globenewswire.com LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
investors.com IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target? LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
globenewswire.com LB Pharmaceuticals to Participate in Upcoming September Investor Events NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
globenewswire.com LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
seekingalpha.com Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO…
globenewswire.com LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into…
globenewswire.com LB Pharmaceuticals Announces $150 Million Private Placement NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
globenewswire.com LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing…
globenewswire.com LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior…
globenewswire.com LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for…
globenewswire.com LB Pharmaceuticals to Participate in Upcoming June Investor Events NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for…
zacks.com All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2…
